Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-05-26
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks